Gwendolyn Binder bought $25k of CABA
President, Science & Tech. at Cabaletta Bio, Inc.. 11,312 shares at an average of $2.19, traded Jan 21, 2026, filed Jan 21, 2026.
Score components
- +20RolePresident
- 0Trade size$25k at market
- +10Relative to holdingsHoldings up 57%
- 0Price contextNo price history yet
- +15Cluster8 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +24.4%, 3m +35.5%, 6m +17.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-018325, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 21, 2026 | POpen-market purchase Common Stock | +11,312 | $2.19 | $25k | 31,312 | Jan 21, 2026 |
Related signals
Other insiders at Cabaletta Bio, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | Cabaletta Bio, Inc. | Catherine Bollard director | $9,982 4,405 shares | +441% | |
| 38Weak | Cabaletta Bio, Inc. | Michael Gerard General Counsel | $15k 6,600 shares | - | |
| 38Weak | Cabaletta Bio, Inc. | Mark Simon director | $25k 11,061 shares | +8% | |
| 50Moderate | Cabaletta Bio, Inc. | Steven Nichtberger President & CEO | $101k 45,000 shares | +5% | |
| 45Moderate | Cabaletta Bio, Inc. | Steve Gavel Chief Commercial Officer | $50k 22,170 shares | - | |
| 45Moderate | Cabaletta Bio, Inc. | Shawn Tomasello director | $50k 22,725 shares | - | |
| 38Weak | Cabaletta Bio, Inc. | David J. Chang Chief Medical Officer | $20k 8,800 shares | - | |
| 3Weak | Cabaletta Bio, Inc. | Gwendolyn Binder See Remarks | $241k 11,000 shares | -35% | |
| 2Weak | Cabaletta Bio, Inc. | Gwendolyn Binder See Remarks | $196k 11,000 shares | -35% | |
| 1Weak | Cabaletta Bio, Inc. | Gwendolyn Binder See Remarks | $147k 11,000 shares | -35% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.